Of all racial/ethnic groups, African Americans and Africans experience a disproportionate burden of premenopausal breast cancer for reasons that remain unknown and understudied. The vast majority of African-Americans originated from West Africa, a region currently estimated to have a population of 200 million persons, of whom more than 120 million is concentrated in Nigeria. In the post genome age, research focused on racial or ethnic group differences is less relevant in view of the dynamic interplay between genes and the environment. Rather, we believe studies should be focused on the individual, each with her unique genetic constitution and history of environmental exposures. We are in a unique position to fill the huge knowledge gaps in the causes of breast cancer in populations of African ancestry by examining a large cohort of African American and Nigerian breast cancer cases. In ongoing work funded through separate R01s, we are collecting comprehensive family and exposure history and have established a large bio-specimen repository of cases and controls from Nigeria that will be invaluable for assessing the reasons why women of African ancestry develop earlier onset and pathologically more aggressive breast cancer. This project aims at testing whether sequence variation in genes involved in the metabolism of sex hormones and xenobiotics (including drugs) influences the risk to breast cancer. We will build on our previous efforts in this area that include large-scale SNP discovery studies guided by comparative genomics analyses involving the UGT1A gene cluster and the CYP3A gene cluster. The goal of this SPORE proposal is to extend our studies and determine whether sequence variation in the UDP-glucuronosyltransferases 2B (UGT2B) family of genes influence the risk to breast cancer. Constructing genetic profiles that could be used to assess risk could also be used to individualize therapy and will increase our understanding of the role of gene environment interactions in breast cancer etiology and treatment. Moreover, because these enzymes are important in the metabolism of anticancer agents, the information obtained through these studies may help in dissecting the genetic bases of inter-individual variability in response to anticancer treatment and, ultimately, lead to individualized therapy. This should ultimately lead to reduced breast cancer morbidity and mortality and improved clinical outcomes for all women with breast cancer.
Our specific aims are:1) Perform a re-sequencing survey of the UGT2B gene cluster based on comparative genomics analyses in ethnically diverse population samples to select tag SNPs for association study;2) Examine whether polymorphic variants of UGT2B genes are associated with breast cancer risk in women of African descent and 3) Examine whether UGT2B genes and environmental factors are associated with age at diagnosis, tumor grade, and ER/PR staining.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA125183-05
Application #
8137160
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
2013-07-31
Budget Start
2010-08-01
Budget End
2011-07-31
Support Year
5
Fiscal Year
2010
Total Cost
$358,708
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Guindalini, Rodrigo Santa; Zheng, Yonglan; Abe, Hiroyuki et al. (2018) Intensive surveillance with bi-annual dynamic contrast-enhanced magnetic resonance imaging downstages breast cancer in BRCA1 mutation carriers. Clin Cancer Res :
Rebbeck, Timothy R (see original citation for additional authors) (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593-620
Zheng, Yonglan; Walsh, Tom; Gulsuner, Suleyman et al. (2018) Inherited Breast Cancer in Nigerian Women. J Clin Oncol 36:2820-2825
Wang, Shengfeng; Ogundiran, Temidayo; Ademola, Adeyinka et al. (2018) Development of a Breast Cancer Risk Prediction Model for Women in Nigeria. Cancer Epidemiol Biomarkers Prev 27:636-643
Debiasi, Márcio; Polanczyk, Carisi A; Ziegelmann, Patrícia et al. (2018) Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis. Front Oncol 8:156
Feng, Ye; Rhie, Suhn Kyong; Huo, Dezheng et al. (2017) Characterizing Genetic Susceptibility to Breast Cancer in Women of African Ancestry. Cancer Epidemiol Biomarkers Prev 26:1016-1026
Hamdi, Yosr; Soucy, Penny; Kuchenbaeker, Karoline B et al. (2017) Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Res Treat 161:117-134
Michailidou, Kyriaki (see original citation for additional authors) (2017) Association analysis identifies 65 new breast cancer risk loci. Nature 551:92-94
Rudin, Shoshana; Marable, Marcus; Huang, R Stephanie (2017) The Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment. Genomics Proteomics Bioinformatics 15:82-93
Geeleher, Paul; Huang, R Stephanie (2017) Exploring the Link between the Germline and Somatic Genome in Cancer. Cancer Discov 7:354-355

Showing the most recent 10 out of 203 publications